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Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic disorder with a 
worldwide prevalence of 5-15% of women of reproductive age. This syndrome is characterised 
by a chronic state of inflammation and insulin resistance (IR). The ethology of PCOS remains 
unclear, although studies indicate that both genetic and environmental factors contribute to it. 
The importance of PCOS in women’s health lies in its relationship with not only endocrine 
disorders (hormonal imbalances), but also metabolic disorders (IR, glucose intolerance, type II 
diabetes, dyslipidaemia, non-alcoholic fatty liver disease); as well as a chronic state of 
inflammation and even, psychiatric disorders. The pathogenesis of PCOS remains unclear, 
however, the latest studies relate the genesis of these mechanisms to the gut microbiota, as it 
seems that gut microbiota composition in patients with PCOS is significantly altered compared 
with healthy controls. We recognize specific bacteria associated with the microbiome of 
patients with PCOS vs control. Gut microbiota can change under PCOS condition, but it has 
also been proposed that dysbiosis of gut microbiota may be a potential pathogenic factor in the 
development of PCOS. In this background, it may be engaging to research on new therapies 
based on the modulation of the gut microbiota, focusing especially on an anti-inflammatory diet 
and probiotics. Regarding to the diagnosis, recent research shows that the study of metabolites 
could be crucial, since diagnosis by exclusion may no longer be warranted.  
 
Resum:  
La síndrome de l'ovari poliquístic (SOP) és un trastorn endocrí-metabòlic comú amb una 
prevalença mundial del 5-15% de les dones en edat reproductiva. Aquesta síndrome es 
caracteritza per un estat crònic d'inflamació i resistència a la insulina (RI). L'etiologia 
del SOP encara no està clara, tot i que els estudis indiquen que tant els factors genètics com els 
ambientals hi contribueixen. La importància del SOP en la salut de les dones resideix en la seva 
relació no només amb trastorns endocrins (desequilibris hormonal), sinó també amb trastorns 
metabòlics (RI, intolerància a la glucosa, diabetis tipus II, dislipèmia, fetge gras no alcohòlic); 
així com un estat crònic d'inflamació i, fins i tot, trastorns psiquiàtrics. La patogènesi 
del SOP encara no està clara, però, els darrers estudis relacionen la gènesi d'aquests 
mecanismes amb la microbiota intestinal, ja que sembla que la composició de la microbiota 
intestinal en pacients amb SOP es troba significativament alterada en comparació amb els 
controls sans. Reconeixem bacteris específics associats al microbioma de pacients amb SOP vs. 
control. La microbiota intestinal pot canviar en condicions de SOP, però també s'ha proposat 
que la disbiosis d’aquesta microbiota pot ser un factor patogènic potencial en el 
desenvolupament del SOP. En aquest context, pot ser interessant investigar sobre noves teràpies 
basades en la modulació de la microbiota intestinal, centrant-se especialment en una dieta 
antiinflamatòria i probiòtics. Pel que fa al diagnòstic, investigacions recents demostren que 
l'estudi dels metabòlits podria ser crucial, ja que així podria deixar d’estar justificat el diagnòstic 
per exclusió. 
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Key teaching points:  
 
• Mechanisms involving the gut microbiota may be a potential pathogenic factor in the 
development of PCOS.  
• Microbiota composition in PCOS patients differs from healthy controls.  
• Studies suggest that obesity, IR and hormonal imbalance could lead to dysbiosis.  







Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic disorder 
among women of reproductive age, with an estimated worldwide prevalence of 5-15% 
when the Rotterdam Consensus criteria are used (1). The syndrome, defined by these 
criteria, is characterised by the presence of at least two of the three classical features of 
PCOS: menstrual irregularity (oligomenorrhoea or amenorrhoea), hyperandrogenism 
(acne, hirsutism), and enlarged “polycystic” ovaries on pelvic ultrasound. It is also 
characterised by a chronic state of inflammation and insulin resistance (IR). It is believed 
that IR and inflammation are responsible for the increased risk of diabetes, metabolic 
syndrome and cardiovascular disease observed in long term PCOS patients (2). 
 
The ethology of PCOS remains unclear, although studies indicate that both genetic 
and environmental factors contribute to the syndrome (3). In anterior years, reviews had 
described adolescent hyperandrogenism or precocious pubarche such as signs that may 
indicate the early stages of PCOS (4).  
 
It is known that a big diversity exists in the clinical presentation of PCOS, because 
not all women diagnosed with it have the same pathological phenotypes (3). PCOS 
phenotypes vary with ethnicity, weight, age and region (5). Even though, the most 
common phenotype is the metabolic one, related to insulin resistance.  
 
PCOS is a diagnosis of exclusion, meaning that secondary causes need to be 
excluded before treating it.  Nowadays, due to the prevalence of this syndrome, alternative 
treatments are gaining much interest among population. It is for this reason that scientific 
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evidence is focusing a lot on the relationship between PCOS and a possible dysbiosis as 
one of the causes or worsening of the clinical picture. 
 
Materials and Methods 
In order to write this bibliographic review a systemic search of different concepts has 
been performed in PubMed and Scopus databases. Keywords used to filter through the 
databases were: PCOS AND (“gut microbiota” OR microbiome OR dysbiosis). For this 
review, the articles included were those that reported the alterations of the intestinal 
microbiota under PCOS condition. Additionally, specific terms were used in the search 
of information regarding to hepatic steatosis (PCOS AND NAFLD) and the urinary 
metabolites (PCOS AND urinary AND metabolites). Regarding the information related 
to dietary treatment, different articles were searched directly from "Nutrients" website. 
Selection criteria for all articles was restricted to a 10-year window, even though most of 
the selected ones have been published in recent 4 years. Furthermore, studies without 
humans as subjects were excluded. Finally, in order to obtain a higher level of scientific 
evidence, the primary selected sources were meta-analyses, reviews and systematic 
reviews; even so, there are as well some clinical research articles. 
 
Results 
Overall, a summary of 24 articles were included, as specifying into the different topics, a 
total of 37 articles and an online website were added later. Based on the first information 
obtained from the abstracts of the articles, a script was made. The following includes the 
topics that will be discussed: 
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1. The human microbiota 
2. Gut microbiota in PCOS: 
2.1. Specific bacteria and obesity 
2.2. Dysbiosis and Insulin Resistance 
2.3 Association between hyperandrogenism and gut microbial dysbiosis 
2.4. Psychiatric disorders and gut-brain axis changes 
2.5. Hepatic steatosis  
2.6. Specific fecal and urinary metabolites 
3. COVID and PCOS  
4. Treatments for PCOS involving the gut microbiota 
 
1. The human microbiota 
The microbiota is the set of microorganisms that colonize the epidermal surface and 
the mucous membranes. Throughout the body, humans have a colonizable total of 400m.  
 
The microbiota is changing with life, as we grow, we create our microbiota. In the 
elderly, the gut microbiota become compositionally unstable and less diverse, events that 
are associated with coexisting conditions and age-related declines in immunocompetence 
(6). The microbiota will change over a lifetime and there are many external factors that 
will influence it. Endogenous and exogenous factors influence the gut microbiota:  
• Endogenous: host genetic features, sex and age. 
• Exogenous: diet, birth, xenobiotics and other drugs, tobacco, ambiental 
contamination, infections, diurnal rhythm… These factors are modifiable.  
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It exists a symbiotic relationship between the bacteria that inhabit our intestines and 
ourselves, since we provide them with a place to live and, in return, they help us in 
multitudes of functions and can even produce essential substances. 
 
The main functions are (7): 
• Antimicrobial protection: avert colonization by other pathogens microorganisms, 
thanks to the "barrier" effect that prevents the entry of bacteria, parasites and 
foreign viruses. 
• Immunomodulation: stimulate the immune system, allowing the individual's own 
substances to be recognized from those that are not. 
• Nutrient metabolism: help digest food and absorb nutrients, providing extremely 
important substances that contribute to the proper functioning of the body. 
Moreover, produce vitamins, such as B and K, which the human body is not 
capable of synthesize. 
 
2. Gut microbiota in PCOS 
During the past decade, science has heavily focussed on the microbiota and its broad 
functions throughout the body. The link between the dysbiosis of gut microbiota and the 
development of PCOS was initially studied in 2012 by Tremellen and Pearce. Afterwards, 
many clinical studies confirmed that gut microbiome composition differs when 
comparing PCOS patients with healthy controls. 
 
Gut dysbiosis, brought about a poor diet, creates an increase in gut mucosal 
permeability, with a resultant decrease of protective bacteria and increase in the passage 
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of lipopolysaccharide from Gram negative colonic bacteria into the system circulation 
(2).  
 
Intestinal microorganisms produce short-chain fatty acids (SCFAs), these metabolites 
play a crucial role in immunomodulation (8). One of the metabolites produced for these 
gut microbes (bile acids) may contribute to the pathogenesis and development of diabetes 
and obesity (9), two typical features in PCOS women.   
 
The intestinal microbiota is also able to regulate circulating estrogen levels (we refer 
to the stroboloma), therefore, is associated with gynecopathy such as endometrial 
hyperplasia, endometriosis, PCOS and infertility (10).  
 
We actually know that not only women with PCOS have alterations of enteric 
microorganisms, but also particular species are related to PCOS phenotypes (11). 
 
There are different possible mechanisms through which gut microbes are associated 
with PCOS. Referring to that, intestinal microbes influence the progression of PCOS by 
upregulating or downregulating hormone secretion, gut-brain mediators, cytokines and 
metabolite production. 
 
For instance, alterations of the gut microbiota and less microbial diversity led to (11):  
• Decreased quantity of interleukin-22 (IL-22). One of the mechanisms refers to IL-
22 upregulating the expression of brown fat-related genes, they can’t be regulated 
with poor levels of IL-22, consequently, brown adipose tissue couldn’t help 
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improving PCOS symptoms. On the other hand, IL-22 might target ovarian 
granulosa cells to ameliorate inflammation.  
 
• Decreased quantity of short-chain fatty acids (SCFAs) in their faecal samples. 
This low production of SCFAs increases the inflammation and insulin resistance 
problem by worsening the translocation of endotoxins across the gut wall. 
 
• Lower levels of gut-brain mediators. The hypothalamus-pituitary gland-gonad 
axis does not work the way it is supposed to due to the lack of YY peptide (PYY) 
and ghrelin.  
 
• Higher concentrations of androgen hormones. Thus, PCOS condition seems to 
have higher levels of Provotella (related with androgen levels such as testosterone 
and androstenedione) and decreased abundance of Lactobacilli (correlated with 
estrone and estradiol levels). This specific microbiota contributes to an androgen 
excess. 
 
Even the PCOS factors remains unclear, we already know that the pathogenesis of 
PCOS not only depends on the genetic factors, but also on the epigenetics. Within the 
environmental factors, our everyday higher exposure to the environmental endocrine 
disruptors have been proposed as an important factor in the develop of the syndrome, as 
they have the ability to interfere with hormone sensitivity systems (12). Knowing that gut 
microbiota is affected by sex hormones, it is worth bearing in mind that, even more 
research is required, it could exist a forthright alteration in gut bacteria due to these 
disruptors (13).  
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One of the most studied endocrine disruptors in relation to PCOS is tributyltin 
(TBT) (14). TBT has a negative role in PCOS, as inhibits aromatase, an enzyme whose 
function is to convert testosterone into estradiol. As a result, reducing the function of this 
enzyme could increase testosterone, worsening the symptoms of PCOS. Other disruptors 
are bisphenol A (BPA) or certain herbicides. 
 
2.1  Specific bacteria and obesity 
Body weight could be influenced by the gut microbiota due to its complex effects 
on appetite and metabolism (15). 
 
As said before, it is currently known that women with PCOS have an altered 
microbiota, different from those without the disease. We can say that women with PCOS 
have decreased alfa-diversity, which represents within-subject microbial diversity, and 
significantly altered microbial composition (beta-diversity) compared with controls 
without PCOS. Several bacterial taxa associated with PCOS status was also correlated 
with metabolic biomarkers such as waist-to-hip ratio and triglycerides (TG) (16). 
 
Comparing bacteria of the microbiomes of patients with PCOS and healthy 
(control) patients, a relationship between PCOS and specific gut microbiota has been 
found (1).  An increase in several taxa at the genus levels, specifically the genus 
Lactobacillus, Escherichia/Shigella (especially in the gut of PCOS women with obesity 
(17)) and Bacteroides was showed compared with controls.  
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It is important to point out that the taxa Parabacteroides distasonis was not only 
elevated in PCOS obese women but also in lean women with PCOS. This shows us an 
altered gut microbiota not only in overweight but also in lean women with this syndrome 
(18). 
 
2.2  Dysbiosis and Insulin Resistance (IR)  
One of the commonest conditions in women’s suffering of PCOS is insulin 
resistance (IR). IR occurs when cells in the muscle, fat, and liver don’t respond well to 
insulin and can’t easily take up glucose from the blood (extra glucose stays in the 
bloodstream rather than entering the cells). As a result, pancreas makes more insulin to 
help glucose enter to the cells. Over time, this plight could develop type 2 diabetes (T2D) 
(19).  
 
Gut microbiota dysbiosis is one of the factors that mediate the appearance of IR 
(and even the subsequent obesity). It seems that IR led to metabolic sequelae such as 
polycystic ovary syndrome or non-alcoholic fatty liver disease (15). 
 
He F and Li Y (20) studied the relation between the gut microbial composition in 
PCOS with IR. Comparing with PCOS without IR and healthy controls, a difference in 
the microbial composition of PCOS with IR was found. It does exist a relative abundance 
of Rothia and Enterococcus in this PCOS-IR patients, suggesting that the bacteria of the 
gut microbiota could potentially play a key role in the pathogenesis of PCOS by 
regulating the glucagon-like peptidin-1 (GLP-1) level.  
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In this context, major risk factors for T2D such as overnutrition and low dietary 
fibre involve the gut and have been found to be associated with increased IR, decreased 
glucose tolerance and local or systemic low-grade inflammation (21).  
 
The leaky gut hypothesis also has to do with alterations of the insulin receptor 
(16). This hypothesis relates to the permeability of the intestinal barrier, caused for a high 
sugar/fat and low dietary fibre diet. As previously stated, this permeability will induce a 
passage into the blood stream of toxins, antigens and bacteria; what finally leads to a 
systemic inflammatory response. The insulin receptor will be altered for this chronic state 
of inflammation, that affects multiple organs and follicular development. IR and the 
following hyperinsulinemia might promote synthesis of testosterone, which, at high 
concentrations can intervene in follicular development (2) [Figure 1 near here]. 
 
Gut dysbiosis and its intestinal mucosal permeability not only increase the passage 
of the mentioned inflammatory mediators, but also produces branch-chain amino acid 
(BCAA) by intestinal microflora. This increase in circulating BCAA activates the 
immune response of the body and reduce insulin sensitivity (22). A recent study found 
that imidazole propionate (microbial metabolite produced from amino acid) was shown 
to have higher concentrations in the portal and peripheral blood of patients with T2D (23). 
 
This excess of insulin in PCOS play an elementary role in the already known 
hyperinsulinemia (24). Excess circulating insulin promote secretion of androgen by ovary 
and adrenal gland, therefore, increasing levels of free testosterone by inhibiting the 
synthesis of sex hormone binding globulin (SHBG) (25). To wit, PCOS with IR is a 
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metabolic problem that causes an alteration in the ovary too.  
 
Furthermore, IR is also related with dyslipidaemia (lipid metabolism disorders); 
pathology seen as the first metabolic disorder in the referred ovary syndrome (26).  
 
Fang-fang He and Yu-mei Li (22) write about the implication of the gut 
microbiota (as an indispensable microbial organ) in the pathogenesis of PCOS. We have 
seen that insulin is linked to the microbiota. Even though, other studies highlight the 
interaction, through signal pathways and transduction, between IR and chronic subclinical 
inflammation (28). Then, gut microbiota might be involved in the pathogenesis of PCOS 
by mediating systemic low-grade inflammation and insulin resistance, also affecting the 
change in sex hormones leading to the acquaintance hyperandrogenism (22,27).  
 
2.3. Association between hyperandrogenism and gut microbial dysbiosis 
 Hyperandrogenism is a medical condition characterized by high levels of 
androgens in females.  This androgen excess results, between other symptoms, in 
ovulation disorders (22), a very representative clinical parameter in women with PCOS.  
 
 A recent study (29) had a deeper investigation in the correlation between gut 
microbiome and hyperandrogenism. This study enrolled 73 PCOS women, of which 62 
had hyperandrogenism. Among the findings, it stands out that the lower alfa-diversity of 
the microbiome (seen as typical in PCOS) strongly correlated (negative correlation) with 
hyperandrogenism, specifically with total testosterone level and hirsutism. It seems that 
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androgens may change the gut microbiome, worsening like this the progression and 
pathology of PCOS.  
 
2.4. Psychiatric disorders and gut-brain axis changes  
We actually know that there is a permanent relationship between our gut and our 
brain. The central nervous system has a constant bidirectional connection with the 
digestive tract. It is for this reason that some people refer to our gut as our “second brain”. 
 
An actual study (18) analysed the relationship between alterations in our intestinal 
microbiota and the prevalence of gut–brain axis changes in PCOS. The study was 
designed to test the possible involvement of the gut microbiota in metabolic disorders and 
neurotransmitter production. 
 
The acquired reports of the above-mentioned study identified a difference in the 
species present in the intestinal microbiota of women with PCOS when compared with 
women without said diagnosis. The study reflected a possible microbial dysbiosis in 
women with PCOS that could be associated with neuroendocrine changes, revealing a 
possible gut-brain axis behind the syndrome. 
 
This dysbiosis can produce an imbalance between gamma aminobutyric acid 
(GABA) producing and consuming bacteria, leading to a significant increase in GABA-
producing bacteria (Parabacteroides distanosis, Bacteroides fragilis and Esterichia coli 
were increased in PCOS against controls (18,30)). These bacteria might increase the level 
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of GABA, acting on the receptors of gonadotrophin-releasing hormone (GnRH) neurons 
in hypothalamus to stimulate the secretion of luteinizing hormone (LH), causing the 
neuroendocrine disorders (18) and the typical increased ratio of LH to follicle-stimulating 
hormone (FSH) in PCOS patients. 
 
Thus far, the point of view has been lately focused on neuroendocrine impairments 
associated with PCOS. This is because psychiatric disorders are more often diagnosed in 
this syndrome (31).  
 
Eating disorders are one of the most common disorders among women with PCOS 
(32). One of the links between PCOS and eating disorders refers to the elevated 
testosterone concentrations, as these levels may promote food cravings, perhaps via a 
poor impulse control (33).  
 
Even so, eating disorders disturb neuroendocrine pathways leading to altered 
biochemical processes. In this way, binge eating, or stress (continuous secretion of 
cortisol) can increase insulin levels, leading to routes that can increase free circulating 
testosterone (31). 
 
Seems that the relationship between psychiatric disorders and PCOS will work in 
both directions, the psychiatric disorders appear to function as cause and consequence.  
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If we take a deeper look, we can conclude that eating disorders can also modify 
the gut microbiota, generally, leading to a reduction in diversity associated with poor 
clinical outcomes (34). Régine P. M. Steegers-Theunissen et al. (31) postulate that the 
exposure to a variety of psychological stressors during puberty and adolescence induces 
chronic psychiatric disorders, which, in some individuals, result in repeated episodes of 
overeating and dieting, collectively contributing to the development of PCOS. This 
psychological distress and its associated eating disorders during these periods lead to the 
epigenetic dysregulation of neurohormones (androgens, oestradiol, insulin, ghrelin…) 
involved in the pubertal upregulation of the hypothalamic–pituitary–gonadal axis (HPG 
axis), which contributes to the development of PCOS and related comorbidities in these 
subjects [Figure 2 near here].                          
 
2.5. Hepatic steatosis  
We already know that women with PCOS have a specific microbiota, but it 
appears that the microbiome is also important in the pathogenesis of the so-called non-
alcoholic fatty liver disease (NAFLD) (35). It is interesting to study the relationship 
between PCOS and NAFLD, since its known that women with PCOS have a higher risk 
of suffering from NAFLD.  
 
At first, a higher prevalence of NAFLD has been observed in women with PCOS 
with a body mass index (BMI) similar to women without PCOS (36). In the case of 
adolescent girls with obesity, the prevalence rate ranged from 50% compared to 13% in 
women without said endocrine disorder (37). 
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To delve into this topic, we will use the study carried out by Jobira B. et al (38), 
in which 34 girls with similar parameters were equally divided into two groups: with and 
without hepatic steatosis (HS). The results of said study were that those adolescents with 
PCOS, obesity and HS had a dysbiosis of the microbiota compared to those with PCOS 
and obesity but without HS. Then, a conclusion comes to light, since it seems that not 
only PCOS and HS affect the microbiota separately, but also, if we add liver dysfunction 
to the sum of PCOS and obesity, we can see other specific changes in the bacterial taxa 
of the gut microbiota. Even so, the question remains about what the jumping-off point is 
and if this relationship between PCOS and HS are causative or just associations. 
 
The study by Del Chierico et al. (39) in pediatric population and the above-
mentioned study (38) agree about their findings in lower amounts of Bacteroidetes in 
HS/NAFLD patients. Adolescent patients with HS were also found to have upregulation 
of ethanol metabolism (39), and according to that, Jobira B et al. found a higher %RA 
Bifidobacterium (alcohol producing bacteria) in their adolescents with HS and PCOS. 
This suggests that bacteria taxa involved in ethanol production may contribute to 
endogenous ethanol production in NAFLD in PCOS (38).    
 
One of the pathogenic mechanisms between NAFLD and PCOS women has to do 
with the accumulation of lipids in the liver (40). The high level of androgens, due to 
hyperandrogenism in these patients, suppress low-density lipoprotein receptors (LDLR) 
gene transcription to prolong the half-life of very low-density lipoproteins (VLDL) and 
LDL, thus causing the mentioned accumulation of lipids.  
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Furthermore, as indicated previously, it is essential to note that IR can increase 
the risk of NAFLD, since a higher prevalence of IR has been observed in women with 
PCOS and NAFLD compared to women with the same endocrinopathy but without 
steatosis (41).     
 
Therefore, given the everyday higher prevalence of NAFLD in young women with 
PCOS and the high risk of developing long-term liver complications, it would be a must 
to recommend a systematic screening of NAFLD in patients with PCOS (42).  
 
On the other hand, one of the factors influencing the development of NAFLD is 
the increased dietary fructose (sugar especially found in fruit, honey, and processed foods 
such as juices and other beverages (43)). This kind of diet led to an increase in the uptake 
of fatty acids to the liver and a reduction in the fat transport of VLDL-triglycerides.  As 
a result, we can find a lot of metabolic and cardiovascular comorbidities related to 
NAFLD, such as metabolic syndrome (present in 41% of NAFLD and 71% of HS 
patients) (44).  
 
The scientific evidence available to date suggests that chronic and excessive 
fructose intake is likely a major contributor to NAFLD pathogenesis [Figure 3 near 
here], figure 3 describes the mechanisms of NAFLD development and the influence of 
nutritional factors (44). So, in light of this, it could be crucial for patients with or at risk 




2.6. Specific fecal and urinary metabolites 
The study carried out by Ling Zhou et al (45) was the first in relate obese patients 
diagnosed with PCOS with the use of fecal metabolomics combined with gut microbiota.  
 
They compared obese patients with and without PCOS, finding a linear 
relationship between gut microbiota, characteristic fecal metabolites and serum sex 
hormones. PCOS obese patients have characteristic intestinal species that correlate with 
fecal metabolites such as: arachidonic acid, dehydroepiandrosterone (DHEA) sulphate 
and taurocholic acid. At the same time, a correlation was also revealed with serum sex 
hormones (DHEAS and testosterone) [Appendix 1 near here]. Thus, it is finally 
determined that fecal metabolites play a key role in the phenotypic changes caused by 
hyperandrogenism. 
 
Another study (46) characterized urinary steroid hormone metabolites of 107 
women (41 diagnosed with PCOS and 66 healthy controls). The results of this study 
showed a specific urinary steroid profile in PCOS patients. The urinary steroid profiling 
reveal androstanediol, estriol, 20βDHcortisone, and cortisol as promising diagnostic 
markers for PCOS. Another function of the microbiota is to interpose in the metabolism 
of steroid hormones. Therefore, even more research is required, having a specific 
microbiota will trigger on specific metabolites.  
 
Between the latest findings associating PCOS and urinary metabolites we found 
the work of Wei Zhou et al. (47). In this study, a variation of metabolic states was found 
in different PCOS subtypes (healthy, with hyperandrogenism and with IR). A panel of 8 
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biomarkers was discovered from PCOS with hyperandrogenism vs IR: ribitol, trans-
aconitic acid, 4-hydroxycyclohexanecarboxylic acid, tartronic acid, glycolic acid, myo-
inositol, oxalic acid and ribonic acid. The area under curve (AUC) for the metabolic 
biomarkers was 0.8363. The AUC reached 0.9065 (with high sensitivity and specificity 
percentages) when combining biomarkers with 2 clinical markers (homeostasis model 
assessment-insulin resistance (HOMA-IR) and free androgen index).  
 
All in all, it seems that the intestinal microbiota and its respective metabolites could 
be used to diagnose PCOS (in a noninvasively way) and better clarify the pathological 
metabolism of the disease. Thus, metabolomics should be considered as an essential 
science for knowing better about the ethology of PCOS. In connection with this, the study 
of metabolites could be crucial, because PCOS diagnosis by exclusion may no longer be 
warranted, and what is more, therapies could be more targeted for every phenotype and 
therefore, be more efficient.  
 
3. COVID and PCOS  
Nowadays, the whole world is facing a pandemic, it is for this reason that severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most current topic. Some recent 
studies have already point out not only the link and implications with gut microbiota, but 
also the connection with PCOS.  
 
Wambier CG and Goren A (48) study and conclude that SARS-CoV-2 it is androgen 
mediated. We come across the fact that the activity of the androgen receptor plays a 
crucial role in the transcription of the transmembrane protease serine 2 (TMPRSS2). 
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Following this path, the priming of the spike proteins by TMPRSS2 it is a basic required 
step for potential infectivity of SARS-CoV-2. This could be one of the reasons why males 
are more vulnerable to the disease, as reported in some studies (48,49).   
 
PCOS women had greater androgen receptor activity than non-PCOS, therefore, a 
greater transcription of TMPRSS2 (50). In summary, the fact of having a hyperandrogenic 
PCOS phenotype might worse the severity of the currently known SARS-CoV-2. Even 
so, another risk factor for both the susceptibility to and the severity of the SARS-CoV-2 
is obesity (and associated IR) (51). In this context, this is another PCOS feature that could 
worsen the severity of the disease.  
 
4. Alternative treatments for PCOS involving the gut microbiota 
The pathogenesis of this disease is not fully understood, it is still a syndrome with an 
exclusion diagnosis, for this reason, therapies are poorly targeted and possibly ineffective. 
The actual chosen treatment after PCOS diagnostic is the use of oral contraceptives. Even 
so, it is worth bearing in mind the undoubtedly growing interest about how to treat PCOS 
with lifestyle changes. It is for this reason that PCOS patients are interested in a more 
functional and integrative treatment.  
 
As it has already been mentioned, it exists a relation between dysbiosis and intestinal 
inflammation, IR and all that this entails (hyperandrogenism, diabetes…). One of the 
bases for the human health is the diet (total energy intake, macronutrient and 
micronutrient composition), which has an important impact on the composition of gut 
microbiota (52).  
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Now, what our field refers to, we will take into account the modulation of the gut 
microbiome through diet as a potential PCOS treatment.  Different studies show that it 
can be very useful to control inflammation through the intake and / or supplementation 
of: 
 
• Omega-3: unsaturated fatty acid rich diets decrease the risk of insulin resistance 
and its related complications; in this way, intake of omega-3 reduces the risk of 
PCOS in women with IR (53,54). 
 
• Vitamin D: this vitamin has a role in different pathways, including insulin 
signalling pathway and ovarian function. Vitamin D supplementation can 
alleviate inflammatory pathways causing IR and ovarian function, therefore, 
alleviating PCOS (53,54,55). 
 
• Curcumin: this polyphenol may improve glycaemic control and lipid metabolism 
in patients with PCOS and metabolic abnormality. The anti-inflammatory 
property of curcumin may also play a role in glucose and lipid metabolisms and 
may mitigate hyperandrogenism. Regarding to this property, it also could inhibit 




• Green tea: it has been seen that this beverage with high amount of antioxidants 
due to its polyphenols content promotes insulin sensitivity and lowers 
testosterone levels (57).  
 
• Isoflavone: a recent study (58) found an improvement in fasting glucose and 
insulin sensitivity in PCOS patients, but not in controls after a short-term 
isoflavone intervention. This flavonoid could also be used as a prebiotic, 
supporting like this the growth of beneficial microbial strains in PCOS women 
(59).  
 
• Probiotic: consumption of the probiotic Bifidobacterium lactis V9 promotes the 
growth of SCFA-producing microbes, such as Faeca libacterium praus-nitzii, 
Butyricimonas, and Akkermansia. These microbes, as well as Bifidobacterium, 
produce increased levels of SCFAs, impacting the secretion of gut-brain 
mediators, including ghrelin and PYY, and regulating like this the levels of sex 
hormones (60). This increase in the production of SCFAs contributes to the 
barrier function of the gut and reduce the translocation of endotoxins across the 
gut wall, which promotes improvements in inflammation levels and IR (14). In 
connection with this, Jamilian et al. (61) prove that co-administration of probiotic 
containing Bifidobacterium, Lactobacillus and selenium to women with PCOS 
resulted in decreased levels of testosterone and hirsutism and had also beneficial 
effects on mental health parameters. 
 
 22 
• Myo-inositol: the effectivity of supplementation with 4g of myo-inositol/day on 
PCOS females has been studied by many authors. Effects of myo-inositol 
treatment in females with PCOS increases insulin sensitivity, decreases 
hyperandrogenism and improves the menstrual cycle (normalizing ovarian 
function) (62).  
 
By and large, improving all these parameters could result in an improved gut 
microbiota, as hyperandrogenism, IR or inflammation could modify gut microbiota 
leading to dysbiosis.  
 
Instead of lifestyle interventions (diet, physical activity, good sleeping habits, stress 
management…), the treatment of PCOS has been approached from many different 
alternative therapies.   
 
Regarding alternative treatments, another therapy for treating gut dysbiosis in PCOS 
is the fecal microbial transplant (FMT) from healthy donors or representative microbes 
from a healthy gut to re-diversify the gut microbiome. Despite the fact that there are 
limited studies to support this idea, experimental studies show promise that adjusting the 
gut microbial community in PCOS patient through FMT could be a great alternative for 





Discussion and conclusion 
The bacteria that inhabit our intestines are responsible of many current diseases, 
as well as our health. Studies have shown that dysbiosis of gut microbiota occurs in 
PCOS: alpha diversity decreases, and the ratio or abundance of some bacteria related to 
obesity, IR, hyperandrogenism, neurological disorders or HS differs from healthy 
controls.  
 
As explained earlier, we focused on the studies about gut microbiota in humans 
with PCOS, leaving aside studies with animal models, which other magazines have not 
done. Moreover, we summarized not only the alterations of the gut microbiota in humans 
with PCOS but also the correlations between the gut microbiota and different PCOS 
features.  
 
At this time there is no cure for PCOS. However, it has been shown from this 
review that with proper treatment, many of the symptoms could be controlled. Having 
into account that every PCOS phenotype have different features and symptoms, more 
studies are required to find out the association between the causes of dysbiosis of the gut 
microbiota and how this affect to the different PCOS phenotypes.  
 
Besides, the heterogenicity of the pathogenesis makes crucial the need for more 
studies to better understand the mechanisms and association between PCOS and gut 
microbiota, and how gut dysbiosis works as cause and/or consequence.  
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Taking everything into consideration, we can reach an agreement and say that diet 
modulation is not only an excellent, but also a low-risk strategy to help change the 
microbiome. As Hippocrates said once “Let food be the medicine, and let medicine be 
the food”. So, in light of this, it would be a must for females with PCOS to focus on the 
microbiota and live a healthy lifestyle, including an anti-inflammatory diet and probiotics.  
 
Additionally, the data obtained from recent studies show us the relationship 
between androgens in PCOS and COVID-19. Hence, knowing about the possible crucial 
paper of gut microbiota in these endocrinopathy, it would be also engaging to investigate 
about the possible relation between PCOS, gut microbiota and the severity of COVID-
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Correlation analysis of gut microbiota, fecal metabolites and serum sex hormones in obese 
PCOS group. (A) Correlation heatmap between seven important differential fecal metabolites 
and the top 30 genera in abundance. (B) Correlation heatmap between serum sex hormones and 
the top 30 genera in abundance. (C) Correlation heatmap between serum sex hormones and 
seven important differential fecal metabolites. Different colors represent correlation level; *p < 
0.05; **p < 0.01, ***p < 0.001. (D) Correlation map among gut microbiota, fecal metabolites 
and serum sex hormones. The red line represents a significant positive correlation, while the 
green line represents a significant negative correlation; the up arrow represents an increase in 
abundance, while the down arrow represents a decrease in abundance; one, two and three arrows 
represents p > 0.05, p < 0.01, and p < 0.001, respectively.  
 









Figure 1. The DOGMA theory for creation of PCOS.  
Taken by Tremellen and Pearce 2012 (2). 













Figure 2. Psychological distress and its associated eating disorders could lead to the epigenetic 
dysregulation of neurohormones, which contributes to the development of PCOS. 












Figure 3. Influence of nutritional factors in the pathogenesis of NAFLD.  
Taken from Pau Vancells et al. 2021 (44). 
 
 
 
